I'm LongbridgeAI, I can summarize articles.The national medical insurance drug catalog and the commercial insurance innovative drug catalog are expected to be released in November 2026 and implemented in January 2027. The National Healthcare Security Administration recently organized on-site negotiations and competitive bidding, with hundreds of companies participating, and 124 drugs outside the catalog being shortlisted, covering key areas such as oncology and rare diseases for innovative drugs. At the same time, adjustments to the commercial insurance catalog are being carried out simultaneously, with 12 drugs entering negotiations. Participating companies include EVEREST MED, Hengrui Pharma, Pfizer, among others, with GLP-1 hypoglycemic drugs and new Alzheimer's drugs receiving attention
According to a report by CCTV News on the 9th, the national medical insurance drug catalog and the commercial insurance innovative drug catalog are expected to be released in November this year, officially implemented from January 1, 2027.
The National Healthcare Security Administration organized on-site negotiations for the 2026 National Basic Medical Insurance Drug Catalog from September 5 to 8, with hundreds of domestic and foreign companies participating. 124 drugs outside the catalog entered the negotiation and bidding phase, with innovative drugs in key areas of public concern such as tumors, rare diseases, chronic diseases, and pediatric medications participating in the negotiations, and are expected to be included in the medical insurance catalog. At the same time, the adjustment of the commercial health insurance innovative drug catalog is also being carried out simultaneously, with 12 drugs entering the on-site price negotiation.
According to previous reports from domestic media, companies participating in the negotiations for the 2026 National Medical Insurance Catalog and the price negotiations for the commercial insurance innovative drug catalog include EVEREST MED (01952), 3SBio (01530), Shijiazhuang Pharmaceutical Group (01093), China Resources Sanjiu (Shenzhen: 000999), Tasly Pharmaceutical (Shanghai: 600535), Hengrui Pharma (01276)(Shanghai: 600276), BeiGene (06160)(Shanghai: 688235), Novo Nordisk, Pfizer, Eli Lilly, Sanofi, Merck, and others. Representatives from several companies that passed the preliminary review of GLP-1 hypoglycemic drugs gathered for the negotiations, including Innovent Biologics (01801) with its Ma Shidu peptide and Pfizer's Enogratide injection; Tonghua Golden Horse (Shenzhen: 000766) had its Alzheimer's new drug Succinic Acid Anvitan Tablets personally negotiated by Chairman Zhang Yufu. (sl)